Calls
Source: S&P Capital IQ transcripts via Xpressfeed · latest indexed call 2026-04-30 · generated 2026-07-22.
Latest call digest
The Cigna Group, Q1 2026 Earnings Call, Apr 30, 2026 · 2026-04-30T12:30:00
Q1 2026 (reported April 30, 2026) was David Cordani's final quarterly call as CEO before Brian Evanko succeeds him on July 1, with Cordani moving to Executive Chair. Prepared remarks led with strength and a raised outlook: total revenue of $68.5 billion, adjusted EPS of $7.79, and a full-year 2026 adjusted EPS guide lifted to at least $30.35. Management paired the beat with two new portfolio-shaping actions — a planned exit of the individual exchange business at the end of 2026 and a strategic review of eviCore — alongside continued progress on the rebate-free "Signature" pharmacy model and 20% adjusted-earnings growth in Specialty and Care Services.
The Q&A was less about the beat and more about the reshaping. Analysts pressed on how and when clients adopt Signature, the economics of the exchange exit and eviCore review, the drivers of specialty strength (biosimilars, Shields), and a sharp jump in the noncontrolling-interest line. Management framed both divestiture actions as proactive with no transaction to discuss, and reiterated that cost trends remain elevated but have not accelerated. Guidance actually stated: full-year adjusted EPS of at least $30.35, Evernorth adjusted income of at least $6.9 billion, Cigna Healthcare pretax adjusted earnings of at least $4.525 billion, and an unchanged full-year medical care ratio range of 83.7% to 84.7%.
Participant coverage from the latest call.
| Group | Participants | Count |
|---|---|---|
| Management | Operator; Ralph Giacobbe — Senior Vice President of Investor Relations, The Cigna Group; David Cordani — Executive Chairman of the Board, The Cigna Group; Brian Evanko — President, CEO & Director, The Cigna Group; Ann Dennison — Executive VP & CFO, The Cigna Group | 5 |
| Analysts | Albert Rice — Health Care Services Analyst, UBS Investment Bank, Research Division; Kevin Fischbeck — Managing Director in Equity Research, BofA Securities, Research Division; Lisa Gill — MD, Head of U.S. Healthcare Technology & Distribution Equity Research and Senior Research Analyst, JPMorgan Chase & Co, Research Division; Scott Fidel — Research Analyst, Goldman Sachs Group, Inc., Research Division; Charles Rhyee — MD & Senior Research Analyst, TD Cowen, Research Division; George Hill — MD & Equity Research Analyst, Deutsche Bank AG, Research Division; Justin Lake — MD & Senior Healthcare Services Analyst, Wolfe Research, LLC; Erin Wilson Wright — Equity Analyst, Morgan Stanley, Research Division; Jason Cassorla — VP & Equity Research Analyst, Guggenheim Securities, LLC, Research Division; David Windley — MD & Equity Analyst, Jefferies LLC, Research Division | 10 |
Curated latest-call exchanges; one row per analyst topic.
| Analyst | Firm | Topic | What changed in Q&A |
|---|---|---|---|
| Albert (A.J.) Rice | UBS | Signature PBM adoption and selling season | Pressed on transition mechanics, client lead times, and how much of the strong 2027 selling season is Signature versus the general market. Management said 2027 is largely the existing models, expects mid-90s retention, and Signature becomes the standard in 2028. |
| Kevin Fischbeck | BofA Securities | Exchange exit and eviCore economics | Asked about capital recaptured from the exchange exit and whether the eviCore review was inbound or strategic, and its accretion. Management called both proactive, said freed capital is not particularly material, and that there is no eviCore transaction to discuss. |
| Lisa Gill | JPMorgan | PBS cost cadence and specialty drivers | Sought the cadence of the roughly $150 million year-over-year PBS earnings step-down and the drivers of specialty strength. Management pointed to large-client renewals plus Signature investment weighted to the back half, and to volumes, biosimilars, and the Shields contribution. |
| Justin Lake | Wolfe Research | Noncontrolling-interest line jump | Dug into the $226 million NCI that more than doubled year-over-year. Management attributed it to a new joint venture with a large client where most economics pass through despite majority ownership, and said it was fully contemplated in guidance. |
| Jason Cassorla | Guggenheim Securities | Medical care ratio bridge | Questioned whether the 79.8% first-quarter MCR beat was fully explained by flu, weather, and exchange seasonality, and asked to bridge the second-quarter step-up. Management cited balanced favorability with no single outsized driver and left full-year MCR guidance unchanged. |
| Scott Fidel | Goldman Sachs | Growth-pillar continuity under new CEO | Asked how Evanko would treat the long-standing growth strategy. He reaffirmed the three core platforms and signaled intensification on data and AI, lower-cost care, and moving further upstream, with no change to the capital-deployment framework. |
| David Windley | Jefferies | GLP-1 program uptake | Asked about uptake across the GLP-1 programs. Management said weight-management coverage is roughly stable year-over-year, EnCircle enrollment continues to grow, and the demand-versus-affordability tension persists pending oral versions and easing supply. |
Theme tracker
Themes are curator-classified across supplied calls.
| Theme | Status | Quarters mentioned | Read-through |
|---|---|---|---|
| Specialty and Care Services / biosimilars | persisted | Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | The consistent growth engine across the window: specialty pharmacy plus biosimilars (HUMIRA, then STELARA at $0 patient out-of-pocket) and the CarepathRx and Shields additions. Specialty and Care Services grew 20% in Q1 2026 and is framed as about 35% of company income. |
| Rebate-free "Signature" pharmacy model | emerged | Q3 2025, Q4 2025, Q1 2026 | Announced on the Q3 2025 call and dominant since. It becomes the standard model in 2028, with a target of at least 50% of Evernorth Pharmacy Benefit Services members by year-end 2028, reframing the PBM story from transparency commitments to a full rebate-free redesign. |
| Elevated medical cost trend | persisted | Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | A standing planning assumption throughout. The language migrated from "broadly in line" in 2024 to "persistently elevated" across 2025; by Q1 2026 management adds that trend has not accelerated, offering potential upside if it decelerates. |
| Stop-loss margin pressure and recovery | persisted | Q4 2024, Q1 2025, Q2 2025, Q3 2025 | Stop-loss drove the Q4 2024 earnings miss and recurred through 2025 as management repriced. A roughly 100 basis point, two-year margin recapture (majority in 2026, remainder 2027) was laid out, and the topic receded from prominence by Q1 2026. |
| Medicare Advantage divestiture | dropped | Q4 2023, Q1 2024, Q2 2024, Q3 2024, Q4 2024, Q1 2025 | The sale of the Medicare businesses to HCSC dominated calls from late 2023 through the early-2025 close, then dropped out of the narrative once completed — a clean case of a theme running its course and disappearing after execution. |
| GLP-1 coverage and clinical programs | persisted | Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q1 2026 | GLP-1s (EnCircle, EnReach, EnGuide) recur every year, consistently framed as a tension between employee demand and employer affordability, with oral versions and easing supply cited as the route to lower net cost. |
| Portfolio shaping and business exits | persisted | Q4 2023, Q3 2024, Q3 2025, Q4 2025, Q1 2026 | A recurring management discipline: group life and disability, then Medicare, and in Q1 2026 the planned individual-exchange exit plus a strategic review of eviCore — each framed as sharpening focus on core growth platforms. |
Guidance ledger
Quotes, calls, and speakers are source-verified; outcomes are curator-classified.
| Verbatim guidance | Call | Speaker | Curator outcome | Outcome note |
|---|---|---|---|---|
| “With the strong first half performance, we continue to have confidence in our full year 2024 adjusted earnings per share outlook of at least $28.40, which represents more than 13% year-over-year growth in EPS.” | The Cigna Group, Q2 2024 Earnings Call, Aug 01, 2024 · 2024-08-01T12:30:00 | Brian Evanko | missed | Full-year 2024 adjusted EPS was reported at $27.33 on the Q4 2024 call, below the reaffirmed at-least-$28.40 outlook; management attributed the shortfall to stop-loss. |
| “And we expect full year 2025 consolidated adjusted income from operations to be at least $7.9 billion or at least $29.50 per share.” | The Cigna Group, Q4 2024 Earnings Call, Jan 30, 2025 · 2025-01-30T13:30:00 | Brian Evanko | kept | The Q4 2025 call reported full-year 2025 adjusted EPS of $29.84, above the initial at-least-$29.50 outlook. |
| “we expect to recapture approximately 100 basis points of margin in the overall Cigna Healthcare segment over the next 2 years with the majority in 2026 and the remaining in 2027.” | The Cigna Group, Q4 2024 Earnings Call, Jan 30, 2025 · 2025-01-30T13:30:00 | Brian Evanko | pending | The stop-loss recovery was scoped across 2026 and 2027; the supplied call history does not extend far enough to confirm completion. |
| “With the first quarter results, we are raising our full year 2025 adjusted earnings per share outlook to at least $29.60.” | The Cigna Group, Q1 2025 Earnings Call, May 02, 2025 · 2025-05-02T12:30:00 | Ann Dennison | kept | Full-year 2025 adjusted EPS was reported at $29.84 on the Q4 2025 call, above the raised at-least-$29.60 outlook. |
| “Our performance through the first 3 quarters gives us the confidence to deliver on our full year 2025 adjusted earnings per share outlook of at least $29.60.” | The Cigna Group, Q3 2025 Earnings Call, Oct 30, 2025 · 2025-10-30T12:30:00 | Ann Dennison | kept | Reaffirmed at least $29.60 for 2025; the Q4 2025 call reported $29.84. |
| “We are confident in our ability to deliver full year 2026 adjusted earnings of at least $30.25 per share and our ability to deliver attractive long-term EPS growth.” | The Cigna Group, Q4 2025 Earnings Call, Feb 05, 2026 · 2026-02-05T13:30:00 | Ann Dennison | pending | 2026 is in progress; on the Q1 2026 call the outlook was raised to at least $30.35, tracking above this initial floor. |
| “With the first quarter results, we are raising our full year 2026 adjusted earnings per share outlook to at least $30.35.” | The Cigna Group, Q1 2026 Earnings Call, Apr 30, 2026 · 2026-04-30T12:30:00 | Ann Dennison | pending | Full-year 2026 results are not yet in the supplied call history. |
Q&A pressure map
Question counts and firms are curator tallies; analyst coverage shown above.
| Topic | Questions | Firms | Pressure / response |
|---|---|---|---|
| Signature model and the 2026 PBM income decline | 5 | JPMorgan, Wolfe Research, UBS, Barclays, BofA Securities | The Q3 2025 call, which introduced the rebate-free model and flagged a 2026 Pharmacy Benefit Services decline, drew the heaviest questioning. Analysts pushed for the magnitude of the decline and 2026 EPS; management gave only directional commentary and explicitly declined to quantify either. |
| Stop-loss margin miss and repricing | 6 | Wolfe Research, Wells Fargo, TD Cowen, Stephens, Barclays, Deutsche Bank | The Q4 2024 miss made stop-loss the dominant line of questioning, with analysts probing the size of the shortfall, the pace of repricing, and why the margin recovery extends into 2027. |
| Medicare Advantage divestiture rationale | 5 | UBS, Wells Fargo, Nephron Research, Stephens, Wolfe Research | When the HCSC sale was announced on the Q4 2023 call, analysts pressed the rationale for exiting a business management still described as attractive and the implications of ceding control of internal medical spend. |
| Exchange exit and eviCore review | 2 | BofA Securities, Morgan Stanley | On the Q1 2026 call, questions centered on capital freed by the exchange exit and whether the eviCore review was proactive or prompted. Management said both actions were proactive with no transaction to discuss. |
Language shifts
Only language evidence verified against the referenced component is shown.
| Observation | Verbatim evidence | Call ID | Component |
|---|---|---|---|
| A candid admission of a miss that broke from the steady "in line with expectations" cadence of the prior 2023–2024 calls, with the shortfall concentrated in stop-loss. | “we're disappointed by the shortfall that we reported in the fourth quarter.” | 1916608175 | 6 |
| Management framed elevated high-cost-claimant pressure as durable rather than transient, a more structural read of cost trend than earlier calls conveyed. | “So we see it as more of a structural shift than something that's temporary.” | 1916608175 | 49 |
| New forward caution specific to the PBM segment, introduced alongside the rebate-free Signature model and its transition costs. | “we expect margin pressure within our Pharmacy Benefit Service segment over the next 2 years.” | 1962900714 | 2 |
| By Q1 2026 the cost-trend language turns modestly more constructive — still elevated, but explicitly not accelerating and framed as potential upside. | “On the positive side, they have not accelerated. They remained elevated.” | 1993036685 | 34 |
Across the history, Cigna is steadily shifting its center of gravity from insurance toward services and specialty, executed through disciplined pruning — group life, then Medicare, and now exchanges and possibly eviCore. Execution against the EPS algorithm has been reliable apart from the stop-loss-driven 2024 miss; the open question the transcripts leave for the debate is whether the rebate-free Signature transition can absorb near-term PBM margin pressure without denting the long-run algorithm as Evanko takes over.